
Claims

1. Use of Compound I or a pharmaceutically acceptable salt thereof



Compound I

in the manufacture of a medicament for the prevention and/or treatment of an organ injury or a condition associated with an organ injury in a subject diagnosed with, or suffering from an infection.

2. The use according to claim 1, wherein the organ injury or condition associated therewith is a consequence of the infection.

3. The use according to any one of claims 1 or 2, wherein the infection is viral, bacterial, fungal, or parasitic.

4. The use according to any one of the preceding claims, wherein the infection is a respiratory infection.

5. The use according to any one of the preceding claims, wherein the infection is a viral infection.

6. The use according to any one of the preceding claims, wherein the organ is selected from a lung, kidney, and/or heart.

7. The use according to any one of the preceding claims, wherein the organ is a lung.

8. The use according to claim 7, wherein the lung injury, or a condition associated with the lung injury is damage to the respiratory tissue e.g. any one or combination of bronchi, bronchioles, alveoli, or tissues associated therewith; alveolar damage; pulmonary or alveolar infiltration, dyspnea; pulmonary edema; pulmonary fibrosis; hypoxemia, pneumonia, bronchiolitis, or a combination thereof.

9. The use according to any one of claims 7 or 8, wherein the lung injury or condition associated with the lung injury is acute hypoxic respiratory insufficiency or failure, acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).

10. The use according to any one of claims 7 to 9, wherein the medicament is to be used for preventing the development, or the progression of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS) in a subject suffering from a respiratory infection.

11. The use according to claim 4 to 10, wherein the infection is a respiratory viral infection and optionally caused by a respiratory virus, e.g. an influenza virus, a rhinovirus, a respiratory syncytial virus, an adenovirus, a coronavirus (CoV), a dengue virus, or a parainfluenza virus.

12. The use according to claim 11, wherein the viral respiratory infection is caused by a coronavirus, and optionally wherein the coronavirus is a SARS-CoV, SARS-CoV2, or MERS-CoV.

13. The use according to claim 12, wherein the respiratory infection is COVID-19.

14. The use according to claim 4 to 10, wherein the infection is a respiratory bacterial infection, and optionally is caused by a gram-negative and/or a gram-positive bacteria, further optionally wherein the bacteria is a pseudomonas bacteria (e.g. pseudomonas aeruginosa), a klebsiella bacteria (e.g. klebsiella pneumoniae), a haemophilius bacteria (e.g. haemophilius influenzae), a streptococcus bacteria (e.g. streptococcus pneumoniae), a staphylococcus bacteria (e.g. staphylococcus aureus), or legionella bacteria (e.g. legionella pneumophila).

15. The use according to any one of the preceding claims wherein the medicament is to be administered to a subject in need thereof before, simultaneously with, and/or after a treatment with oxygen support or mechanical ventilation.

16. The use according to any one of the preceding claims wherein the subject is receiving a second active ingredient, e.g. a corticosteroid such as dexamethasone.

17. The use according to claim 16 wherein the subject is diagnosed with, or suffering from a respiratory infection, and optionally, wherein the medicament is to be used for preventing the development, or the progression of acute lung injury (ALI) or acute respiratory distress syndrome (ARDS).

18. The use according to claim 16 or 17, wherein the medicament is packaged with written instructions for the administration of Compound I to a subject receiving the second active ingredient, wherein the instructions indicate a sequential, or simultaneous administration of the medicament and the second active ingredient.

19. The use according to any one of claims 1 to 6, wherein the organ is a kidney.

20. The use according to claim 19, wherein the kidney injury, or a condition associated with kidney injury is acute kidney injury (AKI).

21. The use according to any one of the preceding claims wherein the medicament is ~~for~~ to beused in the prevention and/or treatment of at least two types of organ injury or condition associated with said organ injuries in a subject with a respiratory infection; optionally wherein the medicament is ~~for~~ to be used in the prevention and/or treatment of lung and kidney injuries and their associated conditions.

22. The use according to any one of the preceding claims, wherein the medicament is to be administered or is adapted for administration to a human subject.

23. The use according to any one of the preceding claims, wherein the medicament is to be administered by injection or infusion, inhalation, or by oral administration.

24. The use according to any one of the preceding claims, wherein the medicament comprises at least one unit dose of Compound I or a pharmaceutically acceptable salt thereof, wherein the unit dose is between about 0.005 to 20 mg/kg.